Jorey Chernett Buys 12,000 Shares of Oncology Institute (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI) major shareholder Jorey Chernett bought 12,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were bought at an average price of $4.75 per share, for a total transaction of $57,000.00. Following the acquisition, the insider directly owned 10,579,858 shares of the company’s stock, valued at $50,254,325.50. This represents a 0.11% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Wednesday, May 20th, Jorey Chernett bought 33,500 shares of Oncology Institute stock. The shares were bought at an average price of $4.07 per share, for a total transaction of $136,345.00.
• On Tuesday, May 19th, Jorey Chernett bought 5,000 shares of Oncology Institute stock. The shares were bought at an average price of $4.05 per share, for a total transaction of $20,250.00.
• On Tuesday, May 19th, Jorey Chernett bought 30,000 shares of Oncology Institute stock. The shares were bought at an average price of $4.09 per share, for a total transaction of $122,700.00.
• On Thursday, April 9th, Jorey Chernett bought 20,000 shares of Oncology Institute stock. The shares were bought at an average price of $3.10 per share, for a total transaction of $62,000.00.
• On Tuesday, March 24th, Jorey Chernett bought 125,000 shares of Oncology Institute stock. The shares were bought at an average price of $3.11 per share, for a total transaction of $388,750.00.
• On Friday, March 20th, Jorey Chernett bought 25,000 shares of Oncology Institute stock. The shares were bought at an average price of $3.35 per share, for a total transaction of $83,750.00.
• On Tuesday, March 17th, Jorey Chernett bought 75,000 shares of Oncology Institute stock. The shares were bought at an average price of $3.42 per share, for a total transaction of $256,500.00.
• On Monday, March 16th, Jorey Chernett bought 60,985 shares of Oncology Institute stock. The shares were bought at an average price of $3.29 per share, for a total transaction of $200,640.65.
• On Friday, March 13th, Jorey Chernett bought 263,000 shares of Oncology Institute stock. The shares were bought at an average price of $2.92 per share, for a total transaction of $767,960.00.

Oncology Institute Stock Performance

TOI opened at $4.87 on Friday. The Oncology Institute, Inc. has a 52-week low of $2.02 and a 52-week high of $5.17. The firm has a market capitalization of $481.35 million, a PE ratio of -13.16 and a beta of 0.37. The business’s 50-day simple moving average is $3.78 and its 200 day simple moving average is $3.40.

Oncology Institute (NASDAQ:TOI) last released its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. The company had revenue of $147.44 million for the quarter, compared to the consensus estimate of $142.10 million. On average, research analysts forecast that The Oncology Institute, Inc. will post -0.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on TOI shares. BTIG Research restated a “buy” rating and issued a $7.00 price objective on shares of Oncology Institute in a research note on Monday, March 9th. Needham & Company LLC restated a “buy” rating and issued a $5.00 price objective on shares of Oncology Institute in a research note on Monday, March 9th. B. Riley Financial upped their price objective on Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Hedge Funds Weigh In On Oncology Institute

A number of large investors have recently made changes to their positions in TOI. Kestra Advisory Services LLC bought a new position in shares of Oncology Institute during the fourth quarter worth approximately $31,000. Pekin Hardy Strauss Inc. bought a new position in shares of Oncology Institute during the fourth quarter worth approximately $36,000. Cetera Investment Advisers increased its stake in shares of Oncology Institute by 35.0% during the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares during the period. State of Wyoming bought a new position in shares of Oncology Institute during the second quarter worth approximately $37,000. Finally, R Squared Ltd bought a new position in shares of Oncology Institute during the fourth quarter worth approximately $41,000. Institutional investors own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.